Hematologic Oncology

Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.

Carrie L. Kitko, MD, discusses outcomes with axatilimab in patients with chronic graft-vs-host-disease according to prior lines of therapy received.

Peter Riedell, MD, highlights the rationale for investigating CAR T-cell therapy rapcabtagene autoleucel in relapsed/refractory DLBCL.

Escalating doses of lymphodepleting chemotherapy with or without rituximab prior to CAR T-cell therapy was safe in relapsed/refractory DLBCL.

The resubmission of a BLA for odronextamab was accepted by the FDA for the treatment of patients with relapsed/refractory follicular lymphoma.

The FDA has granted the novel, oral KAT2A/B degrader AUTX-703 fast track designation for the treatment of patients with relapsed/refractory AML.

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

Odronextamab produced durable responses in relapsed/refractory diffuse large B-cell lymphoma after disease progression following CAR T-cell therapy.

Lorenzo Falchi, MD, discusses the long-term outcomes of fixed-duration epcoritamab plus R-CHOP in previously untreated patients with DLBCL.

Tambiciclib plus zanubrutinib generated responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Non-myeloablative HSCT with TLI/TBI/ATG conditioning was safe and active in eliciting immune quiescence and tolerance.

CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.

Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.

Orca-T with reduced-intensity conditioning displayed robust and early donor myeloid and T-cell engraftment in advanced hematologic malignancies.

Favorable responses were demonstrated with the treatment of axatilimab plus ruxolitinib/belumosudil in heavily pretreated patients with chronic GVHD.

See this full list of regulatory decisions from 2024 regarding withdrawn agents, label updates, and new drug formulations.

A high-risk CAR-HEMATOTOX score was associated with worse outcomes with obe-cel in relapsed/refractory B-ALL.

The designation underscores the potential of the CAR T-cell therapy NXC-201 to serve as a new option in relapsed/refractory AL amyloidosis.

The movement of CAR T-cell therapy to earlier lines of therapy was among many notable advancements greenlit by the FDA in the hematologic space in 2024.

The top 5 videos of the week cover insights in lung cancer, multiple myeloma, breast cancer, and follicular lymphoma.

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.